Blackstone Life Sciences VI Access Fund, L.P.
Raised
$296M
Investors
947
Min Invest
$50,000
Is this your company or fund? Claim this page free.
AltStreet Analysis
·Generated from EDGAR primary sources
Blackstone Life Sciences VI Access Fund, L.P. is a Delaware pooled investment fund that has raised $296.4M from 947 investors under Rule 506(b) and Section 3(c) exemptions. The filing was submitted on 2025-09-24 with a $50K minimum investment. First sale date was not disclosed. iCapital Alternative Investments LLC and Maples Fiduciary Services (Delaware) Inc. are listed as executive officers, with Asterion Fund Services L.L.C. as promoter.
This alternative investment vehicle employs the standard 506(b) private placement exemption combined with 3(c) Investment Company Act relief, typical for private funds. The $50K minimum places it in the accessible-accredited tier, lower than institutional-only vehicles but above retail-focused products, and the 947-investor count suggests a broad access model relative to typical institutional funds.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
AltStreet Coverage
Original reporting from AltStreet's daily EDGAR monitoring covering iCapital and its filings.
Blue Owl Net Lease Trust Form D/A: Investors and Dollars Sold Both Rise 46% in a Year to $9.2 Billion
A Form D/A filed August 27 puts Blue Owl Real Estate Net Lease Trust at 44,524 investors and $9.2 billion sold since inception, both up about 46% from the amendment filed a year earlier, as its September closing added $178.6 million and the $2.45 billion Sila Realty Trust take-private closed on credit-facility borrowings.
Platform coverage · Sep 2026
What Is a Form D Amendment? KKR Infrastructure V's D/A Tops $17 Billion
A Form D amendment updates an existing exempt-offering notice rather than announcing a new raise, and a 2026 filing from a KKR infrastructure fund shows exactly how that distinction plays out in the numbers.
Platform coverage · Sep 2026
iCapital-PEG Evergreen PE Offshore Fund Reports $414M Raised, Up 113% in One Year
A Form D/A filed July 20, 2026 shows total offering proceeds for the iCapital-managed Cayman segregated portfolio company more than doubled versus the prior annual amendment, with investor headcount rising 37% to 224.
Platform coverage · Aug 2026
From 49 to 92 Investors in a Year: A 1972-Vintage Quant Shop Is Quietly Winning the Wealth Channel
The annual Form D amendment iCapital filed August 19 for its Campbell Absolute Return feeder is the kind of document nobody reads — except this one measured something: an 88% jump in investors and $12 million of new capital in twelve months, the largest single-year move AltStreet has recorded for the entity, and a direct reading on how wealth advisers are buying systematic absolute return.
Platform coverage · Aug 2026
iCapital's Blue Owl GP Stakes VI Feeders Report Nearly $816M Sold
The onshore and offshore private-wealth vehicles tied to Blue Owl's GP Stakes VI strategy reported a combined $815.8 million sold and 1,580 investor positions in Aug. 13 SEC amendments, up $16.45 million from their July 2025 filings. The filings show the scale of the iCapital distribution channel, but not when the incremental capital actually arrived.
Platform coverage · Aug 2026
In the Terminal
Filing events
2
latest Sep 24, 2025
Critical / warning
0 / 2
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
closed
Latest event New filer · Sep 24, 2025
SEC.govFund family Part of the Blackstone Life Sciences Access Fund family: 2 vehicles across 1 generation · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- The dated record: 12 facts with source, effective date and capture date, viewable as AltStreet knew them on any past day
- 2 filing events with values and deltas, latest 2025-09-24, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
-- iCapital Alternative Investments LLC
Executive Officer · New York, NY
-- Maples Fiduciary Services (Delaware) Inc.
Executive Officer · Wilmington, DE
-- Asterion Fund Services L.L.C.
Promoter · Wilmington, DE
Edward Truitt, Jr.
Executive Officer · Wilmington, DE
Scott Huff
Executive Officer · Wilmington, DE
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Merrill Lynch, Pierce, Fenner & Smith IncorporatedCRD 7691 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Questions About Blackstone Life Sciences VI Access Fund, L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Blackstone Life Sciences VI Access Fund, L.P.?
Blackstone Life Sciences VI Access Fund, L.P. is a Delaware limited partnership that filed a Form D with the SEC on September 24, 2025 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests. AltStreet links the issuer to iCapital.
Is Blackstone Life Sciences VI Access Fund, L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. Blackstone Life Sciences VI Access Fund, L.P. filed a Form D with the SEC on September 24, 2025 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $296,430,631 sold to 947 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to iCapital, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Blackstone Life Sciences VI Access Fund, L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Blackstone Life Sciences VI Access Fund, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Blackstone Life Sciences VI Access Fund, L.P. raised?
Blackstone Life Sciences VI Access Fund, L.P. reported $296,430,631 sold from 947 investors of a $296,430,631 total offering as of the Form D filed September 24, 2025.
Who can invest in Blackstone Life Sciences VI Access Fund, L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $50,000.
What is the minimum investment in Blackstone Life Sciences VI Access Fund, L.P.?
The Form D lists $50,000 as the minimum investment accepted from any outside investor as of September 24, 2025. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Blackstone Life Sciences VI Access Fund, L.P. and how are they paid?
The Form D names Merrill Lynch, Pierce, Fenner & Smith Incorporated (CRD 7691), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $1,739,195 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Blackstone Life Sciences VI Access Fund, L.P.?
The Form D lists 5 related persons: iCapital Alternative Investments LLC, executive officer; Maples Fiduciary Services (Delaware) Inc., executive officer; Asterion Fund Services L.L.C., promoter (General Partner of the Issuer); Edward Truitt, Jr., executive officer; Scott Huff, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Blackstone Life Sciences VI Access Fund, L.P. located?
The issuer's address on its SEC filings is One Grand Central Place, 60 East 42nd Street 26th Floor, New York, NY 10165. Its phone number of record is 212-994-7400. It is organized under the laws of Delaware.
How long is the Blackstone Life Sciences VI Access Fund, L.P. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Blackstone Life Sciences VI Access Fund, L.P.?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.